Back to Search
Start Over
Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer.
- Source :
-
Molecular cancer [Mol Cancer] 2021 Nov 29; Vol. 20 (1), pp. 151. Date of Electronic Publication: 2021 Nov 29. - Publication Year :
- 2021
- Subjects :
- Ado-Trastuzumab Emtansine therapeutic use
Adult
Aged
Aged, 80 and over
Breast Neoplasms drug therapy
Disease Progression
Female
Gene Amplification
Humans
Middle Aged
Neoplasm Grading
Neoplasm Staging
Prognosis
Ado-Trastuzumab Emtansine pharmacology
Biomarkers, Tumor
Breast Neoplasms diagnosis
Breast Neoplasms etiology
Drug Resistance, Neoplasm genetics
Liquid Biopsy methods
Receptor, ErbB-2 genetics
Receptor, ErbB-2 metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1476-4598
- Volume :
- 20
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Molecular cancer
- Publication Type :
- Report
- Accession number :
- 34839818
- Full Text :
- https://doi.org/10.1186/s12943-021-01438-z